Month: May 2024

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira®REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars...

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira®REYKJAVIK, ICELAND & PARSIPPANY, NJ  — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings...

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix’s proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets. Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable characteristics for use with alpha emitting agents. Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225. Data is supportive of advancement to a therapeutic Phase I/II study in H2 2024.MELBOURNE, Australia, May 21, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)...

Reported figures all in U.S. Dollars Announces Continued, Consistent Revenue Growth with Increasing Fixed Cost Leverage Boston, MA, May 20, 2024 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) today announced its financial results for the 13 weeks ended March 31, 2024 (“Q1 2024”). The fiscal year of MiniLuxe is a 52-week reporting cycle ending on the Sunday closest to December 31, which periodically necessitates a fiscal year of 53 weeks; fiscal years referred to in this release consist of 52-week periods. Unless otherwise specified, all amounts are reported in U.S. dollars. MiniLuxe continued its consistent, organic, year-over-year growth as Q1 2024 revenue increased 8% over Q1 2023 at $5.6M with gross profit of $2.3M, a 2% increase from Q1 2023. The Company views gross profit dollar growth as a key indicator of MiniLuxe’s...

BELO HORIZONTE, Brazil, May 20, 2024 (GLOBE NEWSWIRE) — Inter&Co (NASDAQ: INTR), the financial super app serving over 32 million customers across the Americas, announced today that S&P Global Ratings (S&P) has upgraded Banco Inter outlook to “Stable” and reaffirmed its “brAA+” local rating. In the report S&P stated that: “The stable outlook reflects our view that Inter&Co will continue to improve its profitability, providing greater stability to the business.”  The outlook review was based on several factors such as the noted favorable perceptions for future profitability growth, improved profitability, revenue diversification and an increased loan portfolio. “This positive outlook review reinforces the work we have been putting towards our 60/30/30 north star goal. We...

New offering will be the first of its kind for the OTC markets NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) —  OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated financial markets for 12,000 U.S. and global securities, today introduced OTC Overnight, a new offering that will make OTC equity securities available for trading Sunday through Thursday between 8 PM and 4 AM eastern time. Active securities across the OTC market tiers, including global brands like Roche, Adidas, Air Canada and Techtronic Industries, will be eligible for trading in an overnight session by broker-dealer subscribers in U.S. dollars. OTC Markets expects that OTC Overnight will be available in the second quarter of this year on the OTC Link NQB Alternative Trading System. This will allow investors to track and trade thousands of global equity securities...

HOUSTON, May 20, 2024 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings at the 21st Annual Energy Infrastructure CEO & Investor Conference in Aventura, FL on Wednesday, May 22, 2024. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary domestic...

CINCINNATI, May 20, 2024 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2024. Management Commentary “During the first quarter, we took important strategic and financial actions to better position Workhorse for the future while continuing to hit major milestones,” said Workhorse CEO Rick Dauch. “Our successful W56 demonstrations with dealers and fleet operators continue to affirm the strong market potential of our commercial EV trucks. This April, we celebrated a major milestone with a substantial order for our W4 CC trucks and expanded our dealer network to include new locations in New York and a set of dealership...